Global Acquired Haemophilia Therapeutics Market

Acquired Haemophilia Therapeutics Market is expected to grow at CAGR 5.2% throughout the forecast period to reach USD 19.47 Bn. by 2032.

Acquired Haemophilia is a rare genetic disorder, which is characterized by bleeding that occurs in patients with a negative personal or family history for haemorrhages. Autoimmune disorders occur when the body’s immune system mistakenly attacks healthy cells or tissue. In Acquired Haemophilia (AH), the body produces antibodies that attack clotting factors. Clotting factors are specialized proteins required for the blood to clot normally.To know about the Research Methodology :- Request Free Sample Report

The treatment of Haemophilia comprises two approaches- To control bleeding episodes and other is to reduce inhibitor titer against clotting factor VIII in blood serum. To counter these blood complications, physicians prefer therapeutic drugs such as Desmopressin and Obizur. Increasing geriatric population and exceptional drug pharmacodynamic and pharmacokinetic profile shown by the immunomodulatory therapy are key drivers for the AH therapeutics market growth.

Promising results showed up by the immunomodulatory agents in phase III clinical trials, will increase its demand as the first-line drug therapy to reduce the inhibitors pertaining to clotting factor VIII in the blood serum. However, the high costs associated with the bypassing agents used to control bleeding episodes may hamper market growth.

The report covers the detailed analysis of global Acquired Haemophilia Therapeutics Market with the classifications of the market based on therapy type, Distribution channels, and region. Analysis of past market dynamics from 2020 to 2025 is given in the report, which will help readers to benchmark the past trends with current market scenarios with the key players contribution in it.

The report has profiled fourteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analysing the market and estimation the size of the same. The growing healthcare infrastructure in each region is different and focus is given on availability of advanced technology and new techniques. Report has come up with recommendations for future hot spot in APAC region. New research findings, funding policies for projects and its impact on AH Therapeutics market are covered ion the report.

Acquired Haemophilia Therapeutics Market Segment Analysis

The advanced therapy segment is expected to grow because of advanced tests which are performed often. The first step in AH is to control bleeding, which is done by injecting blood clotting factors. The bypassing agents for this include Activated Factor VII (NovoSevenRT) or Activated Prothrombin Complex Concentrates (aPCC). Hence, as the first line of treatment, these therapeutics are increasing market growth. The market for advanced therapies is expected to grow by $ xx Mn in the forecast period.

Acquired Haemophilia Therapeutics Market Regional Insights

North America is currently dominating the Acquired Haemophilia Therapeutics Market. The factors responsible for market growth are increasing public health awareness regarding autoimmune diseases, which is leading to early diagnosis and treatment. Affordable reimbursement policies for treating acquired haemophilia is expected to strengthen the market growth in this region.

Recent Industry Developments (2025–2026)

Acquired Haemophilia Therapeutics Market Scope:Inquire before buying

Acquired Haemophilia Therapeutics Market, by Region

• North America (United States, Canada and Mexico)
• Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
• Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
• Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
• South America (Brazil, Argentina Rest of South America)

Key players/competitors profile covered in Acquired Haemophilia Therapeutics Market report in strategic perspective

Takeda Pharmaceutical Company Limited
Novo Nordisk A/S
Sanofi
F. Hoffmann-La Roche Ltd
Pfizer Inc.
Bayer AG
Octapharma AG
Grifols, S.A.
CSL Behring
Biogen Inc.
Sobi (Swedish Orphan Biovitrum AB)
LFB S.A.
Kedrion S.p.A
Genentech, Inc.
Emergent BioSolutions Inc.
Aptevo Therapeutics
BioMarin Pharmaceutical Inc.
Spark Therapeutics, Inc.
Sangamo Therapeutics, Inc.
uniQure N.V.
Novo Nordisk Health Care AG
Baxter International Inc.
Bristol-Myers Squibb Company